Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | TSHR | P16473 | 6/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532256 | 0.87 | MAPK1 (0.59) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL532257 | 0.87 | MAPK1 (0.59) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL3490748 | 0.78 | TERT (0.45) | ALDH1A1TSHRALOX15HSD17B10MAPT | |
| SCHEMBL770159 | 0.78 | ALDH1A1 (0.65) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL10300053 | 0.78 | ALDH1A1 (0.65) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL547220 | 0.78 | ALDH1A1 (0.65) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL2702568 | 0.77 | ADRA2A (0.44) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL95662 | 0.77 | NR3C2 (0.47) | ALDH1A1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL65261 | 0.76 | ALDH1A1 (1.00) | ALDH1A1TSHRALOX15HSD17B10MAPK1 | |
| SCHEMBL104811 | 0.76 | APP (0.32) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116841120-A | Composition for preparing ultraviolet-sensitive photoetching silver paste, and preparation method and application thereof | 河北光兴半导体技术有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-113831302-A | Benzisoselenazolone derivative and preparation method and application thereof | 山东大学 | 2021-12-24 | — | — | CN | claimed |
| US-9695141-B2 | Anticancer miliusane derivatives | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-07-04 | — | — | US | claimed |
| US-8951508-B2 | Compound | DSM IP ASSETS B.V. (NL) | 2015-02-10 | — | — | US | claimed |
| CN-102174035-B | Aromatic dihydrazide type PLK1 (Polo-like Kinase 1) inhibitor and applications thereof | UNIV CHINA PHARMA | 2015-01-07 | — | — | CN | claimed |
| EP-2509571-B1 | NOVEL COMPOUND | DSM IP ASSETS BV (NL) | 2014-09-24 | — | — | EP | claimed |
| EP-2509576-B1 | Polyglycerol based UV filter comprising p-dimethylamino benzoate | DSM IP ASSETS BV (NL) | 2014-08-27 | — | — | EP | claimed |
| CN-103145662-A | N-substituted animobutyrolactone derivatives and uses thereof | SHENZHEN WANHE PHARMACEUTICAL CO LTD | 2013-06-12 | — | — | CN | claimed |
| US-20130034511-A1 | NOVEL COMPOUND | DSM IP ASSETS B.V. (NL) | 2013-02-07 | — | — | US | claimed |
| US-20130004437-A1 | NOVEL COMPOUND | DSM IP ASSETS B.V. (NL) | 2013-01-03 | — | — | US | claimed |
| EP-0293651-B1 | Dicyanovinyl-substituted furan derivatives, process for their preparation, and their use | SUEDZUCKER AG (DE) | 1994-02-02 | — | — | EP | claimed |
| WO-1992004450-A1 | HYBRID PLASMINOGEN ACTIVATORS | BEECHAM GROUP PLC (GB) | 1992-03-19 | — | — | WO | claimed |
| US-4916128-A | Thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-04-10 | — | — | US | claimed |
| EP-0259268-A1 | Process for the preparation of optically active beta-lactams | CIBA-GEIGY AG (CH) | 1988-03-09 | — | — | EP | claimed |
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| US-4438136-A | INHIBITION OF THROMBOXANE ACTIVITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-20 | — | — | US | claimed |
| EP-0013608-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-06-15 | — | — | EP | claimed |
| US-4308161-A | FOR UPGRADING BLACK COLOR OF BLACK LIQUID CRYSTAL DISPLAYS | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
| US-4308164-A | Novel yellow azo dyes and dichroic liquid crystal composition made therewith | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
| US-4308163-A | IMPROVING BLACK COLOR OF DICHROIC DYES | GENERAL ELECTRIC COMPANY (US) | 1981-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034511-A1 | NOVEL COMPOUND | MGLL, DGKZ, DGAT2 | ALDH1A1 2800/4885TSHR 3739/4885ALOX15 106/4885 |
| US-20130004437-A1 | NOVEL COMPOUND | MGLL, DGKZ, DGAT2 | ALDH1A1 2800/4885TSHR 3739/4885ALOX15 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.